Market Place
Sourcing Support
Istari Announces First Patient Dosed in NMIBC Substudy of LUMINOS-103 Trial
31 Jan 2023 //
BUSINESSWIRE
Istari Oncology Announces Presentation of Clinical Responses from LUMINOS- 102
18 Oct 2022 //
BUSINESSWIRE
Istari Oncology Presents Positive Data from Ph1 Study of PVSRIPO in Patients
09 Nov 2021 //
BUSINESSWIRE
Istari Oncology Presents Data on Its PVSRIPO Immunotherapy at SITC & SNO
09 Nov 2021 //
BUSINESSWIRE
Dosing begins in PVSRIPO in Istari Oncology’s LUMINOS-103 Phase 1/2 Trial
12 Oct 2021 //
BUSINESSWIRE
First Patient Dosed With PVSRIPO in Istari Oncology’s LUMINOS-103
12 Oct 2021 //
BUSINESSWIRE
Istari Announces FDA Fast Track Designation to PVSRIPO for Advanced Melanoma
14 Jun 2021 //
BUSINESSWIRE
Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO
14 Jun 2021 //
BUSINESSWIRE
Istari Oncology Hires Jamie Iudica as Chief Manufacturing Officer
08 Jun 2021 //
BUSINESSWIRE
Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO
21 Apr 2021 //
BUSINESSWIRE
Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO
21 Apr 2021 //
BUSINESSWIRE
Istari Oncology Announces FDA Clearance of IND to Initiate LUMINOS-103:
19 Apr 2021 //
BUSINESSWIRE
Istari Oncology Abstracts to be Presented at the American Association
06 Apr 2021 //
BUSINESSWIRE
Istari Oncology announces dosing of first subject in melanoma trial
01 Apr 2021 //
CLINICALTRIALSARENA
Istari Oncology Announces First Patient Dosed in the LUMINOS-102 Phase 2
31 Mar 2021 //
BUSINESSWIRE
Istari Oncology Announces First Patient Dosed in the LUMINOS-102 Phase 2
30 Mar 2021 //
BUSINESSWIRE
Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO
11 Jan 2021 //
BUSINESSWIRE
Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO
11 Jan 2021 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.